Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Valproate in Combination with Rituximab and CHOP As First Line Therapy in Diffuse Large B-Cell Lymphoma (VALFRID): Preliminary Results from a Phase I Trial with a Dose Expansion Cohort

Kristina Drott, MD PhD, Hans Hagberg, MD PhD, Thomas Relander, MD PhD, Cecilia Graffman, MD PhD, Johan Drott, PhD, Mats Jerkeman, MD PhD

Blood (2015) 126 (23): 3939.

https://doi.org/10.1182/blood.V126.23.3939.3939

Published: 2015

Journal Articles

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruben Mesa, MD, Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N. Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Shui He, PhD, Mark M Jones, MD, Shreekant Parasuraman, PhD, Jingjin Li, PhD, Isabelle Côté, MD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 709.

https://doi.org/10.1182/blood.V124.21.709.709

Published: 2014

Journal Articles

Langerhans Cell Histiocytosis: A Single Institution Retrospective Analysis of Eleven Patients

Vittorio Stefoni, MD, Alessandro Broccoli, MD, Beatrice Casadei, MD, Enrico Derenzini, MD, Letizia Gandolfi, MD, Cinzia Pellegrini, Federica Quirini, MD, Lisa Argnani, PhD, Pier Luigi Zinzani, MD, PhD

Blood (2014) 124 (21): 5458.

https://doi.org/10.1182/blood.V124.21.5458.5458

Published: 2014

Journal Articles

Demographic Analysis Of 90 Polycythemia Vera Egyptian Cases : An Egyptian Reference Center Experience

Mervat Mattar, MD, Nihad Tawfik, MD, Noha Elhosseiny, MD, Mohamed Morad, MSc

Blood (2013) 122 (21): 5245.

https://doi.org/10.1182/blood.V122.21.5245.5245

Published: 2013

Journal Articles

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD, PhD, Martin Griesshammer, Prof. Dr. med., Tamás Masszi, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Pierre Zachee, MD, PhD, Fabrizio Pane, MD, Claire N Harrison, DM, FRCP, FRCPath, Shui He, PhD, Lance Leopold, MD, Jingjin Li, Ulrich Pirron, PhD, Tomasz Lawniczek, MD, PhD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4071.

https://doi.org/10.1182/blood.V122.21.4071.4071

Published: 2013

Journal Articles

Telangiectasia Macularis Eruptiva Perstans: Report of Three Cases

Gizem Tumer, MD, Tiffany Jow, BS, W. Clark Lambert, MD, PhD

Blood (2011) 118 (21): 5176.

https://doi.org/10.1182/blood.V118.21.5176.5176

Published: 2011

Journal Articles

Deferasirox Decreases Liver Iron Concentration (LIC) in Transfusional Iron Overloaded Patients with Myelodysplastic Syndromes (MDS), Aplastic Anemia (AA) and Other Rare Anemias: Results From 1-Year Multi-Center, Open-Label Phase II Study

Yutaka Kohgo, MD, PhD, Akio Urabe, MD, PhD, Yurdanur Kilinç, MD, Leyla Agaoglu, MD, Krzysztof Warzocha, MD, Guillermo Sanz, MD, Lay Cheng Lim, MD, Silvia Helou, MD, Dany Habr, MD, Isabelle Malet, PharmD, Sabine Glaser, Wieslaw Wiktor-Jedrzejczak, MD

Blood (2011) 118 (21): 4838.

https://doi.org/10.1182/blood.V118.21.4838.4838

Published: 2011

Journal Articles

Reliability of Leukostasis Grading Score to Identify High Risk Patients with Hyperleukocytic Leukemia

Nicola Piccirillo, MD, Luca Laurenti, MD, Patrizia Chiusolo, MD, Federica Sorà, MD, Maria Bianchi, MD, Silvia De Matteis, MD, Livio Pagano, MD, Gina Zini, MD, Giuseppe d’Onofrio, MD, Giuseppe Leone, MD, Simona Sica, MD

Blood (2008) 112 (11): 2979.

https://doi.org/10.1182/blood.V112.11.2979.2979

Published: 2008

Journal Articles

Switching from Deferoxamine (Desferal ® , DFO) to Deferasirox (Exjade ® ) Maintains Effective Control of Iron Levels in Patients with Thalassemia Major (TM)

Maria Domenica Cappellini, Antonis Kattamis, Christos Kattamis, John B Porter, John M Ford, Martha Rodriguez, Lisa Rojkjaer, Antonio Piga

Blood (2008) 112 (11): 5416.

https://doi.org/10.1182/blood.V112.11.5416.5416

Published: 2008

Journal Articles

Ferritin Levels, Compliance and Adverse Events Related to Infused Iron Chelation Therapy in a Cohort of Patients from Usual Care Setting in the United States.

K.A. Payne, M.-P. Desrosiers, I. Proskorovsky, K. Ishak, N. Lordan, J.F. Baladi

Blood (2006) 108 (11): 3360.

https://doi.org/10.1182/blood.V108.11.3360.3360

Published: 2006

Journal Articles

Dramatic and Sustained Hematologic Complete Remission with Denileukin Diftitox (ONTAK®) in a Patient with Refractory Adult T-Cell Leukemia (ATL).

Sheryl L. Ziegler, DO, MS, Connie Augustyniak, RN, Leo I. Gordon, MD, Andrew M. Evens, DO, MS

Blood (2005) 106 (11): 4638.

https://doi.org/10.1182/blood.V106.11.4638.4638

Published: 2005

Journal Articles

Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström’s Macroglobulinemia: Preliminary Safety and Efficacy Results.

Steven P. Treon, MD, MA, PhD, Christopher J. Patterson, BS, Zachary R. Hunter, BS, Andrew R. Branagan, BS

Blood (2005) 106 (11): 2443.

https://doi.org/10.1182/blood.V106.11.2443.2443

Published: 2005

Journal Articles

Clinical and Molecular Findings in Childhood Polycythemia Vera.

Holger Cario, MD, Heike L. Pahl, PhD, Minkov Milen, MD, Reinhard Harald, MD, Elisabeth Kohne, MD, Klaus-Michael Debatin, MD

Blood (2005) 106 (11): 4961.

https://doi.org/10.1182/blood.V106.11.4961.4961

Published: 2005

NARROW

Valproate in Combination with Rituximab and CHOP As First Line Therapy in Diffuse Large B-Cell Lymphoma (VALFRID): Preliminary Results from a Phase I Trial with a Dose Expansion Cohort

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Langerhans Cell Histiocytosis: A Single Institution Retrospective Analysis of Eleven Patients

Demographic Analysis Of 90 Polycythemia Vera Egyptian Cases : An Egyptian Reference Center Experience

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Telangiectasia Macularis Eruptiva Perstans: Report of Three Cases

Deferasirox Decreases Liver Iron Concentration (LIC) in Transfusional Iron Overloaded Patients with Myelodysplastic Syndromes (MDS), Aplastic Anemia (AA) and Other Rare Anemias: Results From 1-Year Multi-Center, Open-Label Phase II Study

Reliability of Leukostasis Grading Score to Identify High Risk Patients with Hyperleukocytic Leukemia

Switching from Deferoxamine (Desferal ® , DFO) to Deferasirox (Exjade ® ) Maintains Effective Control of Iron Levels in Patients with Thalassemia Major (TM)

Ferritin Levels, Compliance and Adverse Events Related to Infused Iron Chelation Therapy in a Cohort of Patients from Usual Care Setting in the United States.

Dramatic and Sustained Hematologic Complete Remission with Denileukin Diftitox (ONTAK®) in a Patient with Refractory Adult T-Cell Leukemia (ATL).

Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström’s Macroglobulinemia: Preliminary Safety and Efficacy Results.

Clinical and Molecular Findings in Childhood Polycythemia Vera.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only